keyword
MENU ▼
Read by QxMD icon Read
search

Crohn's and TNF

keyword
https://www.readbyqxmd.com/read/29448862/filgotinib-for-the-treatment-of-crohn-s-disease
#1
Remi Labetoulle, Stephane Paul, Xavier Roblin
Inflammatory Bowel Diseases, such as Crohn's disease (CD) and Ulcerative Colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence. CD is a chronic, progressive immunologically driven disease, with an evolution characterized by succession of periods of progression and remission. New physiopathological pathways are continuously being discovered, the more we understand about how the disease appears and progresses, the more targets become available for the development of novel therapies...
February 15, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29445293/clinical-utility-of-ustekinumab-in-crohn-s-disease
#2
REVIEW
Paulo Gustavo Kotze, Christopher Ma, Abdulelah Almutairdi, Remo Panaccione
The introduction of anti-tumor necrosis factor (TNF) therapy marked an important milestone in the management of moderate-to-severe Crohn's disease (CD). However, there remains a pressing demand for alternative therapeutic options for patients with primary nonresponse, secondary loss of response, or intolerable side effects to conventional treatment and TNF antagonists. Ustekinumab (UST) is a fully human IgG1κ monoclonal antibody that inhibits the p40 subunit shared by the proinflammatory cytokines, the interleukin (IL)-12 and -23...
2018: Journal of Inflammation Research
https://www.readbyqxmd.com/read/29439003/impact-of-red-and-processed-meat-and-fibre-intake-on-treatment-outcomes-among-patients-with-chronic-inflammatory-diseases-protocol-for-a-prospective-cohort-study-of-prognostic-factors-and-personalised-medicine
#3
Robin Christensen, Berit L Heitmann, Karina Winther Andersen, Ole Haagen Nielsen, Signe Bek Sørensen, Mohamad Jawhara, Anette Bygum, Lone Hvid, Jakob Grauslund, Jimmi Wied, Henning Glerup, Ulrich Fredberg, Jan Alexander Villadsen, Søren Geill Kjær, Jan Fallingborg, Seyed A G R Moghadd, Torben Knudsen, Jacob Brodersen, Jesper Frøjk, Jens Frederik Dahlerup, Anders Bo Bojesen, Grith Lykke Sorensen, Steffen Thiel, Nils J Færgeman, Ivan Brandslund, Tue Bjerg Bennike, Allan Stensballe, Erik Berg Schmidt, Andre Franke, David Ellinghaus, Philip Rosenstiel, Jeroen Raes, Mette Boye, Lars Werner, Charlotte Lindgaard Nielsen, Heidi Lausten Munk, Anders Bathum Nexøe, Torkell Ellingsen, Uffe Holmskov, Jens Kjeldsen, Vibeke Andersen
INTRODUCTION: Chronic inflammatory diseases (CIDs) are frequently treated with biological medications, specifically tumour necrosis factor inhibitors (TNFi)). These medications inhibit the pro-inflammatory molecule TNF alpha, which has been strongly implicated in the aetiology of these diseases. Up to one-third of patients do not, however, respond to biologics, and lifestyle factors are assumed to affect treatment outcomes. Little is known about the effects of dietary lifestyle as a prognostic factor that may enable personalised medicine...
February 8, 2018: BMJ Open
https://www.readbyqxmd.com/read/29430672/review-article-predictors-of-response-to-vedolizumab-and-ustekinumab-in-inflammatory-bowel-disease
#4
REVIEW
A Barré, J-F Colombel, R Ungaro
BACKGROUND: Increased knowledge of pathways involved in the pathogenesis of IBD has led to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis (UC). Two new biological agents have been recently approved for IBD: vedolizumab and ustekinumab. They have different therapeutic targets (α4 β7 integrin for vedolizumab and interleukin-12/23 pathways for ustekinumab) than the primary biological class, anti-tumour necrosis factor alpha (anti-TNF) agents. As the armamentarium for IBD increases in coming years, it will become important to understand factors associated with response in order to best position and personalise therapy...
February 12, 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29422801/efficacy-of-restarting-anti-tumor-necrosis-factor-%C3%AE-agents-after-surgery-in-patients-with-crohn-s-disease
#5
Sakiko Hiraoka, Shiho Takashima, Yoshitaka Kondo, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Seiji Kawano, Keita Harada, Jun Kato, Hiroyuki Okada
Background/Aims: The efficacy of anti-tumor necrosis factor α (anti-TNFα) antibodies for postoperative Crohn's disease (CD) in patients who were treated with these agents prior to surgery is largely unknown. Methods: CD patients who underwent intestinal resection and received anti-TNFα agents after surgery were divided into 2 groups according to the presence or absence of preoperative anti-TNFα treatment: anti-TNFα restart group or anti-TNFα naïve group. Endoscopic recurrence after surgery was examined according to the preoperative conditions, including administration of anti-TNFα agents before surgery...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422799/comparison-of-time-until-elective-intestinal-resection-regarding-previous-anti-tumor-necrosis-factor-exposure-a-brazilian-study-on-patients-with-crohn-s-disease
#6
Paulo Gustavo Kotze, Daniela Oliveira Magro, Barbara Saab, Mansur Paulo Saab, Lilian Vital Pinheiro, Marcia Olandoski, Maria de Lourdes Setsuko Ayrizono, Carlos Augusto Real Martinez, Claudio Saddy Rodrigues Coy
Background/Aims: The use of anti-tumor necrosis factor (anti-TNF) agents seems to reduce surgical rates and delay surgical procedures in prospective trials and population-based studies in the management of Crohn's disease (CD). This study aimed to identify whether preoperative anti-TNF agents influence the time from diagnosis to surgery. Methods: An observational retrospective cohort study was conducted on patients with CD submitted to intestinal resections due to complications or medical therapy failure in a period of 7 years...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422794/asian-organization-for-crohn-s-and-colitis-and-asia-pacific-association-of-gastroenterology-consensus-on-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-receiving-anti-tumor-necrosis-factor-treatment-part-2-management
#7
REVIEW
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri, Suk-Kyun Yang
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29422793/asian-organization-for-crohn-s-and-colitis-and-asia-pacific-association-of-gastroenterology-consensus-on-tuberculosis-infection-in-patients-with-inflammatory-bowel-disease-receiving-anti-tumor-necrosis-factor-treatment-part-1-risk-assessment
#8
REVIEW
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri, Suk-Kyun Yang
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment...
January 2018: Intestinal Research
https://www.readbyqxmd.com/read/29414321/a-novel-th1-type-t-cell-immunity-biasing-effect-of-malate-dehydrogenase-derived-from-mycobacterium-avium-subspecies-paratuberculosis-via-the-activation-of-dendritic-cells
#9
Woo Sik Kim, Jong-Seok Kim, Min-Kyoung Shin, Sung Jae Shin
Mycobacterium avium subspecies paratuberculosis (MAP) is the causative pathogen of Johne's disease in ruminants, characterized by chronic granulomatous enteritis; it also has zoonotic potential and is associated with Crohn's disease in humans. A better understanding of the mycobacterial antigens and their roles in the host immune response may facilitate the rational design of control strategies, including the development of effective vaccines and diagnostic tools. However, the functional roles of a large proportion of MAP antigens involved in modulating the host immune response remain unknown...
February 2, 2018: Cytokine
https://www.readbyqxmd.com/read/29408806/loss-of-function-card8-mutation-causes-nlrp3-inflammasome-activation-and-crohn-s-disease
#10
Liming Mao, Atsushi Kitani, Morgan Similuk, Andrew J Oler, Lindsey Albenberg, Judith Kelsen, Atiye Aktay, Martha Quezado, Michael Yao, Kim Montgomery-Recht, Ivan J Fuss, Warren Strober
In these studies we evaluated the contribution of the NLRP3 inflammasome to Crohn's disease (CD) in a kindred containing individuals having a missense mutation in CARD8, a protein known to inhibit this inflammasome. Whole exome sequencing and PCR studies identified that the affected individuals had a V44I mutation in a single allele of the T60 isoform of CARD8. The serum levels of IL-1β in the affected individuals were increased compared with that in healthy controls and their peripheral monocytes produced increased amounts of IL-1β when stimulated by NLRP3 activators...
February 6, 2018: Journal of Clinical Investigation
https://www.readbyqxmd.com/read/29406811/vedolizumab-for-the-treatment-of-crohn-s-disease
#11
Marjorie Argollo, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Crohn's disease (CD) is an immune-mediated condition characterized by inflammation of the gut tissue, associated with progressive damage of the affected intestinal tract and possible complications. A treat-to-target approach is strongly advocated, consisting of early and aggressive inflammatory control. However, a great proportion of affected subjects lack response or are intolerant to conventional therapy. Even though the first-line biologic therapy targeting tumor necrosis factor-alfa (TNF-α) is associated with improvement of inflammation in some patients, others do not respond at first or lose response over time...
February 6, 2018: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29401297/long-term-outcome-of-early-combined-immunosuppression-versus-conventional-management-in-newly-diagnosed-crohn-s-disease
#12
Daniël R Hoekman, Judith A Stibbe, Filip J Baert, Philip Caenepeel, Philippe Vergauwe, Martine De Vos, Daniel W Hommes, Marc A Benninga, Severine A Vermeire, Geert R D'Haens
Background and Aims: Long term outcomes of early combined immunosuppression (top-down) compared to conventional management (step-up) in recently diagnosed Crohn's disease (CD) are unknown. We aimed to investigate long-term outcomes of participants of the Step-up/Top-down-trial. Methods: Trial participants' medical records were reviewed retrospectively. For 16 semesters following the 2-year trial, we recorded: clinical activity, medication use, flares, hospitalization, surgery and fistulas...
February 1, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29385469/anti-tnf-therapeutic-drug-monitoring-in-post-operative-crohn-s-disease
#13
Emily K Wright, Michael A Kamm, Peter De Cruz, Amy L Hamilton, Fabiyola Selvaraj, Fred Princen, Alexandra Gorelik, Danny Liew, Lani Prideaux, Ian C Lawrance, Jane M Andrews, Peter A Bampton, Simon L Jakobovits, Timothy H Florin, Peter R Gibson, Henry Debinski, Finlay A Macrae, Douglas Samuel, Ian Kronborg, Graham Radford-Smith, Richard B Gearry, Warwick Selby, Sally J Bell, Steven J Brown, William R Connell
Background: Anti-TNF prevents post-operative Crohn's disease recurrence in most patients but not all. This study aimed to define the relationship between adalimumab pharmacokinetics, maintenance of remission and recurrence. Methods: As part of a study of post-operative Crohn's disease management, some patients undergoing resection received prophylactic post-operative adalimumab. In these patients, serum and faecal adalimumab concentration and serum anti-adalimumab antibodies (AAA) were measured at 6, 12 and 18 months post-operatively...
January 27, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29378524/therapeutic-preferences-and-outcomes-in-newly-diagnosed-patients-with-crohn-s-diseases-in-the-biological-era-in-hungary-a-nationwide-study-based-on-the-national-health-insurance-fund-database
#14
Zsuzsanna Kurti, Akos Ilias, Lorant Gonczi, Zsuzsanna Vegh, Petra Fadgyas-Freyler, Gyula Korponay, Petra A Golovics, Barbara D Lovasz, Peter L Lakatos
BACKGROUND: Accelerated treatment strategy, including tight disease control and early aggressive therapy with immunosuppressives (IS) and biological agents have become increasingly common in inflammatory bowel disease (IBD). The aim of the present study was to estimate the early treatment strategy and outcomes in newly diagnosed patients with Crohn's disease (CD) between 2004 and 2008 and 2009-2015 in the whole IBD population in Hungary based on the administrative database of the National Health Insurance Fund (OEP)...
January 30, 2018: BMC Gastroenterology
https://www.readbyqxmd.com/read/29374617/efficacy-of-medical-therapies-for-fistulizing-crohn-s-disease-systematic-review-and-meta-analysis
#15
REVIEW
Matthew J Lee, Claire E Parker, Sarah R Taylor, Leonardo Guizzetti, Brian G Feagan, Alan J Lobo, Vipul Jairath
BACKGROUND & AIMS: Fistulas are debilitating complications of Crohn's disease (CD) that affect up to 50% of patients. We conducted a systematic review and meta-analysis of randomized controlled trials to assess the efficacy of treatments for fistulizing CD. METHODS: We searched publication databases from inception through December 13, 2016 for trials comparing the efficacy of a therapeutic agent (single or combination) with placebo or another active therapy in adult patients with any form of fistulizing CD...
January 25, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29372477/loss-of-response-to-anti-tumor-necrosis-factor-alpha-therapy-in-crohn-s-disease-is-not-associated-with-emergence-of-novel-inflammatory-pathways
#16
Jay Luther, Manish Gala, Suraj J Patel, Maneesh Dave, Nynke Borren, Ramnik J Xavier, Ashwin N Ananthakrishnan
BACKGROUND: While monoclonal antibodies against tumor necrosis factor-α (TNFα) are effective in treating Crohn's disease (CD), approximately one-third of patients lose response. The mechanisms underlying this loss of response remain elusive. AIM: We sought to determine if novel biological pathways, including TNFα-independent inflammatory pathways, emerge in those with loss of response to anti-TNFα. METHODS: Using RNA microarray technology in 28 patients with CD, we examined the colonic gene expression differences between those with active inflammation in the setting of loss of response to TNFα-antagonist therapy ("loss of responders") compared to anti-TNFα naïve patients with active inflammation and those on anti-TNF therapy in disease remission...
January 25, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29364909/intestinal-fibrosis-is-associated-with-lack-of-response-to-infliximab-therapy-in-crohn-s-disease
#17
Jessica R de Bruyn, Marte A Becker, Jessica Steenkamer, Manon E Wildenberg, Sybren L Meijer, Christianne J Buskens, Willem A Bemelman, Mark Löwenberg, Cyriel Y Ponsioen, Gijs R van den Brink, Geert R D'Haens
INTRODUCTION: Overt fibrostenotic disease is a relative contraindication for anti-TNF therapy in Crohn's disease. We hypothesized that subclinical fibrosis may also contribute to an incomplete response to anti-TNF therapy before the onset of symptomatic stenosis. METHODS: In a previous trial, patients with ileocecal Crohn's disease were randomized to either immediate ileocecal resection or medical treatment with Infliximab. In case of insufficient response to Infliximab, the latter underwent secondary ileocecal resection...
2018: PloS One
https://www.readbyqxmd.com/read/29363355/biologic-induced-infections-in-inflammatory-bowel-disease-the-tnf-%C3%AE-antagonists
#18
Sean M McConachie, Sheila M Wilhelm, Ashish Bhargava, Pramodini B Kale-Pradhan
OBJECTIVE: To review the mechanism and association of infectious risk among the tumor-necrosis factor α (TNF-α) antagonists used in inflammatory bowel disease. DATA SOURCES: A PubMed literature search was performed using the following search terms: infliximab, adalimumab, certolizumab, golimumab, inflammatory bowel disease, crohn's, ulcerative colitis, adverse effects, adverse events, safety, and infection. STUDY SELECTION AND DATA EXTRACTION: Meta-analyses and cohort studies with outcomes pertaining to quantitative infectious risk were reviewed...
January 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29361101/systematic-review-with-meta-analysis-anti-tnf-therapy-in-refractory-pouchitis-and-crohn-s-disease-like-complications-of-the-pouch-after-ileal-pouch-anal-anastomosis-following-colectomy-for-ulcerative-colitis
#19
Mathilde Huguet, Bruno Pereira, Marion Goutte, Félix Goutorbe, Anne Dubois, Gilles Bommelaer, Anthony Buisson
Background: Inflammatory complications including chronic refractory pouchitis and Crohn's disease (CD)-like complications of the pouch are common complications after ileal pouch-anal anastomosis (IPAA) following colectomy for ulcerative colitis (UC). We performed a systematic review and meta-analysis to evaluate the efficacy of anti-TNF therapy in distinguishing patients with chronic refractory pouchitis from those with CD-like complications of the pouch. Methods: We performed a systematic literature search to identify articles and abstracts reporting anti-TNF agents efficacy in treating inflammatory complications of the pouch after IPAA for UC...
January 18, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29361093/postoperative-morbidity-risks-following-ileocolic-resection-for-crohn-s-disease-treated-with-anti-tnf-alpha-therapy-a-retrospective-study-of-360-patients
#20
Ingrid Jouvin, Jérémie H Lefevre, Ben Creavin, Sophie Pitel, Najim Chafai, Emmanuel Tiret, Laurent Beaugerie, Yann Parc
Background: Despite the effectiveness of anti-TNF alpha (ATA) treatment to induce and maintain remission in Crohn's disease, surgical intervention is frequently required. Results of previous studies on the impact of anti-TNF on postoperative course are discordant. The aim of this study was to evaluate the impact of ATA on postoperative morbidity following ileocolic resection for Crohn's disease. Methods: A retrospective review of Crohn's disease patients undergoing ileocolic resection was performed...
January 18, 2018: Inflammatory Bowel Diseases
keyword
keyword
24145
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"